BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II.

ABSTRACT: For decades, BCG immunotherapy has been the standard of care for non-muscle-invasive bladder cancer. Despite this clinical experience, the mechanism by which BCG stimulates tumor-eliminating immunity is unclear, and there is still a need for more accurate prediction of clinical outcomes in advance of treatment initiation. We have shown that BCG stimulates tumor-specific T-cell immunity that requires tumor cell expression of the IFNγ receptor (IFNGR); however, the downstream components of IFNGR signaling responsible for responsiveness to BCG are unknown. Here, we demonstrate that the IFNγ-driven, tumor cell intrinsic expression of the class II transactivator CIITA is required for activation of a tumor-specific CD4 T-cell response and BCG-induced tumor immunity. Despite the established role

SUBMITTER: Redelman-Sidi G 

PROVIDER: S-EPMC9532361 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature